Ofev slows progression of IPF beyond four years with consistent safety

Results from INPULSIS-ON, published today in Lancet Respiratory Medicine, provide insights into the long-term safety, efficacy and tolerability of Ofev (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF).

These data suggest that the effect of Ofev on slowing disease progression of IPF persists beyond four years. Results also indicate that the long-term efficacy of Ofev in reducing disease progression may be sustained in patients who require dose adjustments, said the drug’s marketer, German family-owned pharma major Boehringer Ingelheim..

The exploratory findings of the open-label extension trial are consistent with results from the Phase III INPULSIS trials and show that continued treatment with Ofev, for up to 68 months, has a manageable safety and tolerability profile, with no new safety signals identified. The INPULSIS-ON trial featured a large cohort of patients with IPF who received Ofev, and these data add to the growing body of evidence suggesting that Ofev provides long-term benefits to patients with IPF.